首页> 美国卫生研究院文献>British Journal of Pharmacology >Histamine pharmacology: from Sir Henry Dale to the 21st century
【2h】

Histamine pharmacology: from Sir Henry Dale to the 21st century

机译:组胺药理学:从亨利戴尔爵士到21世纪

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Histamine has been one of the most studied substances in medicine, playing a major role in diverse (patho)physiological processes. It elicits its multifaceted modulatory functions by activating four types of GPCRs, designated as H1–4. Despite the heterogeneity and the complexity of histamine receptor pharmacology, many discoveries over the past 100 years resulted in the development of H1 antihistamines and H2‐targeting ‘blockbuster’ therapeutics for the management of allergies and gastrointestinal disorders respectively. Recently, a first‐in‐class H3 inverse agonist was approved for the treatment of narcolepsy, whereas H4 antagonists are under clinical evaluation for their potential therapeutic exploitation in immune‐related diseases. This review critically presents the past successes and drawbacks in histamine research, complemented by the modern conceptual innovations in molecular and receptor pharmacology. It targets both young and experienced researchers in an ongoing effort to stimulate novel insights for the dissection of the translational potential of histamine pharmacology.
机译:组胺已经在医学研究最多的物质之一,在不同的(病理)发挥了重要作用的生理过程。它通过激活四种类型的GPCR,被指定为H1-4引起其多方面调节功能。尽管异质性和组胺受体药理学的复杂性,在过去的100年中,许多的发现导致了H1抗组胺药和H2分别靶向“重磅炸弹”治疗过敏和肠胃功能紊乱的管理的发展。近日,先入级H3反相激动剂被批准用于发作性睡病的治疗,而H4拮抗剂临床评价下在免疫相关疾病的潜在治疗剥削。本次审查严格呈现组胺研究过去的成功和缺点,在分子和受体药理学的现代概念的创新补充。它的目标在不断努力,以刺激新的见解组胺药理学的平移潜力的解剖年轻和经验的研究人员。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号